Netherlands Biochips Market (2025-2030)
The Netherlands Biochips Market was valued at $207.9 Million in 2025 and projected to reach to $299.3 Million by 2030, representing a compound annual growth rate of 7.6%. The Netherlands biochips market is poised for significant expansion through 2030, driven by increasing investments in precision medicine and diagnostic innovation.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Netherlands Biochips Market Trends and Insights
- Netherlands is establishing itself as a key hub for biochip innovation and adoption within Europe, driven by strong healthcare infrastructure and research capabilities.
- The market in Netherlands reflects growing demand for point-of-care diagnostics, personalized medicine applications, and advanced laboratory automation across Dutch healthcare institutions and biotech companies. Growth in the Netherlands biochips market is supported by increasing investments in life sciences research, collaborations between academic institutions and industry players, and regulatory support for medical device innovation.
- Netherlands continues to attract biochip manufacturers and developers seeking to establish European operations, further strengthening the regional market position.
- The forecast period through 2030 indicates sustained expansion as Netherlands leverages its technological expertise and healthcare sector maturity to capture emerging opportunities in genomics, proteomics, and organ-on-chip technologies..
Key Market Statistics
- CAGR (2025-2030) 7.6% CAGR
- Market Size, 2025 ~USD 207.9 Million
- Forecast, 2030 ~USD 299.3 Million
- Country Netherlands
Netherlands Biochips Market Overview
Market Valuation :
The Netherlands biochips market is valued at USD 207.9 million in 2025, with a projected value of USD 299.3 million by 2030, demonstrating strong growth potential in the European biochip sector.
Growth Trajectory :
Netherlands exhibits a CAGR of 7.6% from 2025 to 2030, outpacing many European counterparts and reflecting robust adoption of biochip technologies across healthcare and research institutions.
Innovation Hub Status :
The Netherlands is positioning itself as a key European hub for biochip innovation, leveraging world-class research institutions, advanced healthcare infrastructure, and strong government support for life sciences development.
Healthcare Infrastructure Advantage :
Strong healthcare systems and research capabilities in the Netherlands drive biochip adoption for diagnostics, personalized medicine, and drug development, creating sustained market demand.
Netherlands Biochips Market Dynamics
- The country's robust healthcare infrastructure, combined with leading research institutions and biotech clusters, creates an ideal environment for biochip technology adoption and development.
- Government initiatives supporting life sciences and digital health further accelerate market growth. Key growth drivers include rising demand for point-of-care diagnostics, personalized treatment approaches, and integration of biochips in clinical workflows.
- The Netherlands' strategic position within Europe, coupled with strong pharmaceutical and medical device sectors, positions it as a critical market for biochip manufacturers and healthcare providers seeking advanced diagnostic solutions..
Related Ecosystem
Advanced Genetic Sequencing
- Polymerase Chain Reaction (PCR)
- Reagents
- Assay Kits
- Bioinformatics
- Flow Cytometry
- Thermo Fisher Scientific Inc.
- Illumina, Inc.
- Agilent Technologies, Inc.
- Qiagen N.V.
- Danaher Corporation
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Key Takeaways
- Netherlands biochips market valued at USD 207.9 million in 2025, growing at 7.6% CAGR through 2030
- Strong research infrastructure and healthcare system in Netherlands drive adoption of advanced biochip technologies
- Netherlands serves as a European innovation hub attracting biochip manufacturers and biotech investments
- Personalized medicine and point-of-care diagnostics are primary growth drivers in the Netherlands market
Biochips Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | MICROFLUIDICS (Fabrication Technology) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 8.8% from 2025 to 2030 |
| Largest Segment | MICROARRAYS (Fabrication Technology) |
| Market Size Base Year (Billions) | ~USD 14.01 (2025) |
| Revenue Forecast (Billions) | ~USD 21.36 (2030) |
| Segments Covered | Products & Services, Type, Application, Fabrication Technology, End User, Product & Service |
Netherlands Biochips Market Report Segmentation
6 segment dimensions are covered across the global market.
By Products & Services
- Consumables
- Instruments
- Software & Services
By Type
- Cell Arrays
- Dna Chips
- Lab-On-A-Chip
- Protein Chips
- Tissue Arrays
By Application
- Agricultural Biotechnology
- Cancer Diagnosis & Treatment
- Clinical Diagnostic
- Diagnostics
- Drug Discovery
- Expression Profiling
- Gene Expression
- Genomics
- High-Throughput Screening
- Ivd & Poc
- Other Dna Chip Applications
- Other Loac Applications
- Other Protein Chip Applications
- Proteomics
- Snp Genotyping
By Fabrication Technology
- Microarrays
- Microfluidics
By End User
- Academic & Research Institutes
- Biotechnology & Pharmaceutical Companies
- Contract Research Organizations
- Hospitals & Diagnostic Centers
- Other End Users
By Product & Service
- Consumables
- Instruments
- Software & Services
NETHERLANDS: BIOCHIPS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 19.1 | 20.4 | 21.8 | 23.4 | 25 | 26.8 | 28.7 | 30.8 | 7.1 |
| BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES | 99 | 106.8 | 115.3 | 124.5 | 134.4 | 145.2 | 157.1 | 170.2 | 8.1 |
| CONTRACT RESEARCH ORGANIZATIONS | 11.7 | 12.8 | 13.9 | 15.1 | 16.5 | 18 | 19.6 | 21.4 | 9 |
| HOSPITALS & DIAGNOSTIC CENTERS | 40.4 | 42.7 | 45.2 | 47.9 | 50.8 | 53.9 | 57.2 | 60.8 | 6.1 |
| OTHER END USERS | 10.3 | 11 | 11.7 | 12.4 | 13.3 | 14.2 | 15.1 | 16.2 | 6.7 |
| TOTAL | 180.5 | 193.6 | 207.9 | 223.3 | 239.9 | 258 | 277.8 | 299.3 | 7.6 |
Target Audience
- Biochip Manufacturers & Developers : Manufacturers need Netherlands-specific market data to assess market size, growth potential, and competitive positioning, enabling strategic expansion decisions and product localization for this key European market.
- Healthcare Providers & Hospitals : Dutch healthcare institutions require market insights to evaluate biochip technology adoption, understand clinical applications, benchmark against peers, and make informed procurement and integration decisions.
- Pharmaceutical & Biotech Companies : Life sciences companies need Netherlands market intelligence to identify diagnostic partnership opportunities, understand precision medicine adoption rates, and develop targeted commercialization strategies for the region.
- Investment & Private Equity Firms : Investors require detailed Netherlands biochips market analysis to evaluate investment opportunities, assess portfolio company growth potential, and identify emerging players in this high-growth European sector.
- Healthcare Policy & Government Bodies : Dutch healthcare authorities and policymakers need market data to inform regulatory frameworks, funding decisions, and strategic initiatives supporting biochip innovation and adoption within the national healthcare system.
Key Companies in the Netherlands Biochips Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| ATS AUTOMATION TOOLING SYSTEMS INC | Canada | Public Company | Custom automated manufacturing and assembly systems,Pre- and post-automation services,Software and digital factory solutions, |
| DECODE GENETICS | Iceland | Private Company | Internal discovery and target validation for Amgen,External research collaborations and licensing,Population genomics and healthcare-linked projects, |
| JABIL | United States | Public Company | Regulated Industries (Healthcare, Automotive, Industrial, Packaging),Intelligent Infrastructure (5G, Cloud, Networking, Storage, Digital Building),Connected Living and Digital Commerce (Mobility, Connected Devices, Retail, Digital Commerce Ecosystem), |
| AT&S | Canada | Public Company | Turnkey automation systems (design, build, commissioning),Lifecycle services (pre- and post-automation, maintenance, retrofits),Contract manufacturing and integration, |
| X-FAB | Belgium | Public Company | Automotive analog & mixed-signal (incl. high-voltage, BCD, safety ICs),Power semiconductors (SiC, GaN, high-voltage discretes),MEMS & sensor platforms (pressure, inertial, image, gas/flow, photodiodes), |
| GE HEALTHCARE | United States | Public Company | Imaging,Advanced Visualization Solutions (AVS),Patient Care Solutions (PCS), |
| THERMO FISHER SCIENTIFIC INC. | United States | Public Company | Life Sciences Solutions,Analytical Instruments,Specialty Diagnostics, |
| ILLUMINA, INC. | United States | Public Company | Sequencing instruments,Sequencing consumables (reagents, flow cells, library prep, WGS and targeted kits),Array-based instruments and consumables, |
| AGILENT TECHNOLOGIES, INC. | United States | Public Company | Life Sciences and Diagnostics Markets,Agilent CrossLab,Applied Markets, |
| QIAGEN | Netherlands | Public Company | Sample technology consumables and instruments,Immune response (TB and transplant) assays,Oncology, sexual and reproductive health assays, |
| BIO-RAD LABORATORIES, INC. | United States | Public Company | Clinical Diagnostics systems, reagents, and quality controls,Life Science instruments and consumables for research and biopharma,Informatics and software solutions, |
| ABBOTT | United States | Public Company | Diagnostic Products,Medical Devices,Nutritional Products, |
| STANDARD BIOTOOLS | United States | Public Company | Proteomics platforms and consumables (SomaScan, CyTOF, Hyperion),Genomics platforms and consumables (Biomark X9 and qPCR systems),Services, software, and other, |
| 10X GENOMICS | United States | Public Company | Chromium instruments,Chromium consumables & kits (incl. QuantumScale),Visium spatial platform (instruments, slides, reagents), |
| CEPHEID | United States | Private Company | GeneXpert instruments,Xpert test cartridges (infectious disease & HAIs),Xpert test cartridges (virology, oncology, genetics), |
| BIOMéRIEUX | France | Public Company | Clinical microbiology (VITEK, BACT/ALERT, CHROMID, culture media, ETEST, API),Molecular diagnostics (BIOFIRE, SPOTFIRE, ARGENE, EMAG/NUCLISENS, EPISEQ),Immunoassay and sepsis markers (VIDAS, Hybiome CLIA), |
| REVVITY | United States | Public Company | Diagnostics & Immunodiagnostics (prenatal, newborn, infectious, autoimmune, specialty),Life Science Reagents & Assay Platforms,Genomic & NGS Workflow Solutions, |
| DIASORIN S.P.A. | Italy | Public Company | Immunodiagnostics (LIAISON XL / XS reagents and systems),Molecular diagnostics (Simplexa, LIAISON PLEX assays),xMAP technology and other specialty IVD solutions, |
ATS AUTOMATION TOOLING SYSTEMS INC
ATS Automation Tooling Systems Inc. is a Canadian public company founded in 1978 that employs 7,000 people. The company specializes in automation and tooling systems for industrial applications.
DECODE GENETICS
Decode Genetics is a private Icelandic company founded in 1996 with 331 employees. The company focuses on genetic research and analysis.
JABIL
Jabil is a large American public company founded in 1966 with 135,000 employees. The company provides electronics manufacturing services and solutions.
AT&S
AT&S is a Canadian public company founded in 1978 with 7,000 employees. The company specializes in automation and tooling systems.
X-FAB
X-FAB is a Belgian public semiconductor company founded in 1992 with 4,300 employees. The company manufactures specialty semiconductor products.
GE HEALTHCARE
GE Healthcare is an American public company founded in 2022 with 54,000 employees. The company provides medical imaging, diagnostics, and healthcare IT solutions.
THERMO FISHER SCIENTIFIC INC.
Thermo Fisher Scientific Inc. is a large American public company founded in 1956 with 125,000 employees. The company provides laboratory equipment, reagents, and services for research and diagnostics.
ILLUMINA, INC.
Illumina, Inc. is an American public company founded in 1998 with 8,625 employees. The company develops and manufactures DNA sequencing and genetic analysis systems.
AGILENT TECHNOLOGIES, INC.
Agilent Technologies, Inc. is an American public company founded in 1999 with 18,000 employees. The company provides analytical instruments and software for life sciences and diagnostics.
QIAGEN
Qiagen is a Dutch public company founded in 1984 with 5,500 employees. The company develops and manufactures molecular diagnostics and sample preparation products.
BIO-RAD LABORATORIES, INC.
Bio-Rad Laboratories, Inc. is an American public company founded in 1952 with 7,450 employees. The company manufactures and distributes life science research and clinical diagnostics products.
ABBOTT
Abbott is a large American public company founded in 1888 with 115,000 employees. The company develops and manufactures pharmaceuticals, diagnostics, and medical devices.
STANDARD BIOTOOLS
Standard Biotools is an American public company founded in 1999 with 387 employees. The company develops microfluidic and single-cell analysis solutions.
10X GENOMICS
10X Genomics is an American public company founded in 2012 with 1,178 employees. The company develops single-cell and spatial genomics solutions.
CEPHEID
Cepheid is an American private company founded in 1996 with 1,700 employees. The company manufactures molecular diagnostics and point-of-care testing systems.
BIOMéRIEUX
bioMérieux is a French public company founded in 1963 with 14,894 employees. The company develops and manufactures in vitro diagnostics and microbiology testing systems.
REVVITY
Revvity is an American public company founded in 1937 with 11,000 employees. The company provides analytical instruments, software, and services for life sciences and diagnostics.
DIASORIN S.P.A.
DiaSorin S.p.A. is an Italian public company founded in 1968 with 3,242 employees. The company develops and manufactures in vitro diagnostic products.
Reasons to Buy this Report
- Market-Specific Sizing & Forecasts : Access precise valuation data for the Netherlands biochips market (USD 207.9M in 2025) with detailed 5-year forecasts, enabling accurate budget allocation and investment planning specific to this high-growth European market.
- Competitive Landscape Intelligence : Understand the competitive dynamics, key players, and market positioning strategies within the Netherlands biochips sector to identify partnership opportunities and competitive advantages in this emerging innovation hub.
- Regional Growth Drivers & Trends : Gain insights into Netherlands-specific factors driving the 7.6% CAGR, including healthcare infrastructure developments, regulatory environment, research initiatives, and adoption patterns unique to the Dutch market.
- Strategic Market Entry Guidance : Develop informed go-to-market strategies for the Netherlands with detailed analysis of customer segments, distribution channels, reimbursement landscapes, and healthcare system requirements specific to this region.
- Investment & Partnership Opportunities : Identify high-potential investment targets, collaboration opportunities, and acquisition candidates within the Netherlands biochips ecosystem, supported by comprehensive market data and growth projections.
Frequently asked questions
What is the current size of the biochips market in Netherlands?
The Netherlands biochips market is valued at USD 207.9 million in 2025 and is expected to reach USD 299.3 million by 2030.
What is the projected growth rate for biochips in Netherlands?
The Netherlands biochips market is projected to grow at a compound annual growth rate (CAGR) of 7.6% from 2025 to 2030.
What factors are driving biochip market growth in Netherlands?
Key drivers include strong healthcare infrastructure, robust research institutions, increasing demand for personalized medicine, point-of-care diagnostics, and supportive regulatory environment in Netherlands.
Why is Netherlands important for the European biochips market?
Netherlands serves as a major innovation hub in Europe due to its advanced research capabilities, skilled workforce, strategic location, and established biotech ecosystem that attracts international biochip manufacturers.
What biochip applications are most prevalent in Netherlands?
Primary applications in Netherlands include genomics analysis, proteomics research, organ-on-chip platforms, point-of-care diagnostics, and personalized medicine solutions across academic and clinical settings.
RESEARCH METHODOLOGY
This research study extensively utilized both primary and secondary sources. It involved analyzing various factors influencing the industry to identify segmentation types, industry trends, key players, the competitive landscape, key market dynamics, and strategies employed by key players.
Secondary Research
This research study utilized a variety of comprehensive secondary sources, including directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet, white papers, annual reports, company house documents, investor presentations, and SEC filings from various companies. Secondary research was employed to gather information crucial for an in-depth, technical, market-oriented, and commercial analysis of the biochips market. This approach also helped identify key players in the industry and allowed for classification and segmentation based on emerging trends at the most detailed level. Furthermore, significant developments pertaining to both market and technological perspectives were documented. A database of primary industry leaders was created as part of this secondary research.
Primary Research
In the primary research process, we interviewed a range of sources from both the supply and demand sides to gather qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the biochips market. Primary sources from the demand side include researchers in biotechnology and pharmaceutical companies, healthcare professionals from hospitals and diagnostic centers, academic & research institutes and contract research organizations.
A breakdown of the primary respondents is provided below:
Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.
Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The total size of the biochips market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.
Data Triangulation
After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.
Market Definition
The biochips market refers to miniaturized analytical platforms integrating biological probes or microfluidic components that allow simultaneous or rapid analysis of DNA, RNA, proteins, metabolites, or tissues. They are fabricated as microarrays, microfluidic cartridges, or tissue arrays and used in diagnostics, genomics, proteomics, drug discovery, and pathology research. These biochips enable high-throughput screening, providing faster, more efficient testing methods, and are critical in applications such as personalized medicine, disease detection, and environmental monitoring. With advances in technology, biochips are becoming increasingly versatile, supporting the development of novel diagnostics and therapeutic solutions across multiple sectors.
Stakeholders
- Pharmaceutical Companies
- Biotechnology Companies
- Research Institutes
- Academic Institutes
- Contract Research Organizations
- Research and Consulting Companies
- Biochip Manufacturers and Distributors
- DNA & Gene Chip Manufacturers and Distributors
- Protein Microarray Manufacturers and Distributors
- Lab-on-a-Chip Manufacturers and Distributors
- Cell & Tissue Array Manufacturers and Distributors
Report Objectives
- To define, describe, segment, and forecast the biochips market by products & services, type, fabrication technology, end user, and region
- To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biochips market
- To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
- To forecast the size of the biochips market in five main regions (along with their respective key countries): North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa
- To profile the key players in the biochips market and comprehensively analyze their core competencies and market shares
- To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships
Get the Full Biochips Market Report
Full forecast, segment splits, and company analysis for all Biochips Market.
- Canada Biochips Market
- US Biochips Market
- Germany Biochips Market
- UK Biochips Market
- France Biochips Market
- Italy Biochips Market
- Spain Biochips Market
- China Biochips Market
- Japan Biochips Market
- India Biochips Market
- Australia Biochips Market
- South Korea Biochips Market
- Thailand Biochips Market
- New Zealand Biochips Market
- Brazil Biochips Market
- Mexico Biochips Market
- Rest Of Europe Biochips Market
- Rest Of Asia Pacific Biochips Market
- Rest Of Latin America Biochips Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report
